I-MabNASDAQ:IMAB
- LAST PRICE1.6000
- TODAY'S CHANGE (%)0.1000 (6.6667%)
- Bid / Lots1.5600/ 3
- Ask / Lots1.6000/ 57
- Open / Previous Close1.5000 / 1.5000
- Day Range
- 52 Week Range
- Volume153,189
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IMAB |
|---|---|---|
| 09:32 ET | 7506 | 1.535 |
| 09:36 ET | 1344 | 1.515 |
| 09:39 ET | 100 | 1.5 |
| 09:43 ET | 851 | 1.52 |
| 09:48 ET | 710 | 1.51 |
| 09:54 ET | 1400 | 1.51 |
| 09:56 ET | 1000 | 1.51 |
| 10:01 ET | 138 | 1.5176 |
| 10:10 ET | 1053 | 1.5013 |
| 10:19 ET | 165 | 1.52 |
| 10:21 ET | 196 | 1.519 |
| 10:24 ET | 503 | 1.5197 |
| 10:33 ET | 3900 | 1.515 |
| 10:39 ET | 4669 | 1.52 |
| 10:42 ET | 500 | 1.535 |
| 10:44 ET | 25962 | 1.545 |
| 10:46 ET | 21523 | 1.599 |
| 10:48 ET | 4558 | 1.595 |
| 10:50 ET | 300 | 1.595 |
| 10:51 ET | 1600 | 1.595 |
| 10:53 ET | 1700 | 1.59 |
| 10:55 ET | 400 | 1.59 |
| 11:00 ET | 100 | 1.59 |
| 11:02 ET | 3595 | 1.59 |
| 11:04 ET | 4161 | 1.5988 |
| 11:08 ET | 100 | 1.58 |
| 11:09 ET | 300 | 1.58 |
| 11:11 ET | 1000 | 1.59 |
| 11:18 ET | 200 | 1.585 |
| 11:20 ET | 1799 | 1.585 |
| 11:22 ET | 500 | 1.57 |
| 11:27 ET | 408 | 1.5649 |
| 11:29 ET | 300 | 1.5798 |
| 11:33 ET | 221 | 1.5649 |
| 11:36 ET | 4501 | 1.565 |
| 11:38 ET | 200 | 1.5606 |
| 11:40 ET | 184 | 1.5694 |
| 11:42 ET | 620 | 1.565 |
| 11:44 ET | 100 | 1.565 |
| 11:54 ET | 300 | 1.565 |
| 11:56 ET | 1071 | 1.57 |
| 11:58 ET | 100 | 1.565 |
| 12:02 ET | 250 | 1.5694 |
| 12:03 ET | 200 | 1.5697 |
| 12:07 ET | 252 | 1.5699 |
| 12:09 ET | 100 | 1.5606 |
| 12:18 ET | 400 | 1.565 |
| 12:23 ET | 100 | 1.565 |
| 12:32 ET | 300 | 1.57 |
| 12:36 ET | 2500 | 1.58 |
| 12:43 ET | 300 | 1.5798 |
| 12:57 ET | 1680 | 1.57 |
| 01:10 ET | 1086 | 1.575 |
| 01:14 ET | 631 | 1.5797 |
| 01:15 ET | 500 | 1.5706 |
| 01:19 ET | 100 | 1.57 |
| 01:30 ET | 100 | 1.56 |
| 01:35 ET | 411 | 1.565 |
| 01:37 ET | 100 | 1.565 |
| 01:57 ET | 167 | 1.56 |
| 02:00 ET | 300 | 1.56 |
| 02:11 ET | 233 | 1.56 |
| 02:20 ET | 232 | 1.56 |
| 02:24 ET | 1000 | 1.56 |
| 02:26 ET | 100 | 1.565 |
| 02:27 ET | 100 | 1.56 |
| 02:54 ET | 100 | 1.56 |
| 02:58 ET | 825 | 1.5698 |
| 03:14 ET | 500 | 1.565 |
| 03:18 ET | 100 | 1.56 |
| 03:20 ET | 10248 | 1.5799 |
| 03:21 ET | 7801 | 1.575 |
| 03:23 ET | 200 | 1.575 |
| 03:25 ET | 400 | 1.575 |
| 03:30 ET | 315 | 1.5794 |
| 03:32 ET | 200 | 1.575 |
| 03:34 ET | 118 | 1.5794 |
| 03:36 ET | 840 | 1.575 |
| 03:38 ET | 100 | 1.575 |
| 03:43 ET | 600 | 1.575 |
| 03:48 ET | 387 | 1.575 |
| 03:50 ET | 413 | 1.58 |
| 03:52 ET | 228 | 1.585 |
| 03:54 ET | 200 | 1.585 |
| 03:56 ET | 100 | 1.585 |
| 03:57 ET | 1293 | 1.585 |
| 03:59 ET | 2321 | 1.6 |
Jun 6, 2024
Press Release: I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer, from 7:00AM ET on Thursday Jun 06, 2024 by Dow Jones
7:00AM ET on Thursday Jun 06, 2024 by Dow JonesI-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer, from 7:00AM ET on Thursday Jun 06, 2024 by Dow Jones
7:00AM ET on Thursday Jun 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
I-Mab | 129.4M | -0.7x | --- |
PharmaCyte Biotech Inc | 17.7M | -1.3x | --- |
Ibio Inc | 16.6M | -0.1x | --- |
PolyPid Ltd | 19.2M | -0.3x | --- |
Aptorum Group Ltd | 21.3M | -4.3x | --- |
KALA BIO Inc | 19.4M | -0.5x | --- |
Company Information
I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.
Contact Information
- Headquarters
- Suite 400, 2440 Research BlvdROCKVILLE, MD, United States 20850
- Phone
- 301-670-2800
- Fax
- ---
Executives
- Interim Independent Chairman of the Board
- Pamela Klein
- Chief Executive Officer, Director
- Rajkumar Kannan
- Chief Financial Officer
- Joseph Skelton
- Chief Medical Officer
- Phillip Dennis
- Chief Medical Officer
- John Hayslip
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $129.4M |
|---|---|
Revenue (TTM) | $3.8M |
Shares Outstanding | 80.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.08 |
EPS | $-2.42 |
Book Value | $2.93 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 34.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -5,059.30% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
